MK-7684A, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4280A clinical trials

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

This study is looking at new treatments for a type of early bladder cancer that hasn't responded to usual therapy. We are testing medicines like pembrolizumab (Keytruda) alone or with other drugs to see if they can help patients whose cancer is considered high-risk.